Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

Investigational New Drugs

Volumn 29, Issue 6, 2011, Pages 1370-1380

  Tortorici, Michael A ^a   Toh, Melvin ^a,d   Rahavendran, S V ^a   LaBadie, Robert R ^a   Alvey, Christine W ^a   Marbury, Thomas ^b   Fuentes, Ernesto ^c   Green, Matthew ^a   Ni, Grace ^a   Hee, Brian ^a   Pithavala, Yazdi K ^a  

^a PFIZER INC   (United States)

^b ORLANDO CLINICAL RESEARCH CENTER   (United States)

^c Elite Research Institute   (United States)

^d CK Life Sciences ^*  (Hong Kong)

Author keywords

Axitinib; Hepatic impairment; Pharmacokinetics; Tolerability; Vascular endothelial growth factor

Indexed keywords

AXITINIB; ANGIOGENESIS INHIBITOR; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOSE RESPONSE; DRUG CLEARANCE; DRUG EXPOSURE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; LETHARGY; LIVER DYSFUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; TIME TO MAXIMUM PLASMA CONCENTRATION; CASE CONTROL STUDY; CLINICAL TRIAL; COMPUTER SIMULATION; HOSPITALIZATION; LIVER DISEASE; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; SMOKING;

ADMINISTRATION, ORAL; ADULT; ANGIOGENESIS INHIBITORS; CASE-CONTROL STUDIES; COMPUTER SIMULATION; FEMALE; HUMANS; IMIDAZOLES; INDAZOLES; LIVER DISEASES; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SMOKING;

EID: 84856035432     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9477-4     Document Type: Article

References (22)

1. Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O'Connor P, Shalinsky DR, Bender SL (2008) Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 14:7272-7283. doi:10.1158/1078-0432. CCR-08-0652
2. Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo J, Trask PC, Kim S, Rini BI (2007) Axitinib treatment in patients with cytokinerefractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 8:975-984. doi:10.1016/S1470-2045 (07) 70285-1 (Pubitemid 47629888)
3. Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP (2009) Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 27:4462-4468. doi:10.1200/JCO.2008.21.7034
4. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB (2008) Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26:4708-4713. doi:10.1200/JCO.2007.15.9566
5. Schiller JH, Larson T, Ou SH, Limentani S, Sandler A, Vokes E, Kim S, Liau K, Bycott P, Olszanski AJ, von Pawel J (2009) Efficacy and safety of axitinib in patients with advanced nonsmallcell lung cancer: results from a phase II study. J Clin Oncol 27:3836-3841. doi:10.1200/JCO.2008.20.8355
6. Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G (2005) Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 23:5474-5483. doi:10.1200/JCO.2005.04.192
7. Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, Rostami-Hodjegan A (2009) The Simcyp ((R)) Population-based ADME Simulator. Expert Opin Drug Metab Toxicol Feb. 6 [Epub ahead of print] doi:10.1517/17425250802691074
8. US Department of Health and Human Services Food and Drug Administration (2003) Guidance for industry pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. US Food and Drug Administration Center for Drug Evaluation and Research. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm072123.pdf. Accessed 2 November 2009
9. Child CG, Turcotte JG (1964) Surgery and portal hypertension. In: Child CG (ed) The liver in portal hypertension. WB Saunders, Philadelphia, pp 50-52
10. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60:646-649
11. U. S. Department of Health and Human Services Food and Drug Administration CfDEaRC, Center for Veterinary Medicine (CVM) (2001) Guidance for industry bioanalytical method validation. US Food and Drug Administration Center for Drug Evaluation and Research. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf. Accessed 24 May 2010
12. Viswanathan CT, Bansal S, Booth B, DeStefano AJ, Rose MJ, Sailstad J, Shah VP, Skelly JP, Swann PG, Weiner R (2007) Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. AAPS J 9:E30-42. doi:10.1208/aapsj0901004 (Pubitemid 46296546)
13. Nakai D, Kumamoto K, Sakikawa C, Kosaka T, Tokui T (2004) Evaluation of the protein binding ratio of drugs by a micro-scale ultracentrifugation method. J Pharm Sci 93:847-854. doi:10.1002/jps.20012 (Pubitemid 38420397)
14. Pithavala YK, Tortorici M, Toh M, Garrett M, Hee B, Kuruganti U, Ni G, Klamerus KJ (2010) Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers. Cancer Chemother Pharmacol 65:563-570. doi:10.1007/s00280-009-1065-y
15. European Medicines Agency (2005) Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function. EMEA (European Medicines Agency) Web site. http://www.emea.europa.eu/ pdfs/human/ewp/23390en.pdf. Accessed 2 November 2009
16. Pang KS, Rowland M (1977) Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 5:625-653 (Pubitemid 8253670)
17. Pang KS, Rowland M (1977) Hepatic clearance of drugs. II. Experimental evidence for acceptance of the "well-stirred" model over the "parallel tube" model using lidocaine in the perfused rat liver in situ preparation. J Pharmacokinet Biopharm 5:655-680 (Pubitemid 8253671)
18. Pang KS, Rowland M (1977) Hepatic clearance of drugs. III. Additional experimental evidence supporting the "well-stirred" model, using metabolite (MEGX) generated from lidocaine under varying hepatic blood flow rates and linear conditions in the perfused rat liver in situ preparation. J Pharmacokinet Biopharm 5:681-699 (Pubitemid 8253672)
19. MacKichan JJ (2006) Influence of protein binding and use of unbound (free) drug concentrations. In: Burton ME, Shaw LM, Schentag JJ, Evans WE (eds) Applied pharmacokinetics & pharmacodynamics-principles of therapeutic drug monitoring. Lippincott Williams & Wilkins, Philadelphia, pp 82-120
20. Blaschke TF (1977) Protein binding and kinetics of drugs in liver diseases. Clin Pharmacokinet 2:32-44 (Pubitemid 8040880)
21. Verbeeck RK (2008) Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 64:1147-1161. doi:10.1007/s00228-008-0553-z
22. Sesardic D, Boobis AR, Edwards RJ, Davies DS (1988) A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol 26:363-372